NCT03554174 - Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

July 8, 2021

Study Completion Date

September 30, 2025

Conditions

Major Depressive Disorder

Interventions

DRUG

Low Dose Psilocybin

0.1 mg/kg psilocybin capsule

DRUG

Placebo

microcrystalline cellulose capsule

DRUG

Medium Dose Psilocybin

0.3 mg/kg psilocybin capsule

Trial Locations (1)

VA Connecticut Healthcare System, West Haven Campus, West Haven